Skip to main content
. Author manuscript; available in PMC: 2021 Aug 17.
Published in final edited form as: J Natl Compr Canc Netw. 2020 Jul;18(7):856–865. doi: 10.6004/jnccn.2020.7534

Table 4.

Predictors for SNF Success in Outcomes at 6 Months - Established Cancer Patients (OR (95% CI) unless otherwise specified)

Variable Any Treatment Death Hospice Hospice LOS < 3 30-day Readmission Months to Death HR* (95% CI)
N=1411 N=1397 N=805 N=460 N=1397 N=1397
c=0.64 c=0.75 c=0.66 c=0.57 c=0.62
Male (vs. Female) 1.66 (1.30–2.11) 1.22 (1.08–1.37)
Age (years) at Index Admission 0.96 (0.94–0.98) 1.015 (1.01–1.024)
Months between Diagnosis and Index Admission 0.95 (0.93–0.97)
White NH (vs. Other) 1.54 (0.99–2.38)
Married or Partnered (vs. Non-married)
Urban 1.85 (1.15–2.98) 1.27 (1.001–1.61)
SES
Per Capita Income ($1000)
Median Income ($1000)
% of Residents below Poverty
% of Non-High School Grads
Charlson Comorbidity Index Categories 1.16 (1.04–1.29)
Cancer Type (vs. Colorectal)
Lung 2.83 (2.05–3.92) 1.32 (0.97–1.79) 1.85 (1.53–2.22)
Pancreas 3.55 (2.23–5.65) 1.07 (0.68–1.69) 2.36 (1.86–3.00)
Bladder 1.66 (0.93–2.97) 2.07 (1.26–3.41) 1.2 (0.87–1.70)
Cancer Stage (vs. Stage IV)
Stage II 0.60 (0.45–0.80) 0.31 (0.22–0.42) 0.74 (0.54–1.02) 0.52 (0.44–0.61)
Stage III 0.94 (0.73–1.22) 0.33 (0.24–0.44) 0.71 (0.53–0.94) 0.55 (0.47–0.63)
Grade** (vs. 9)
1 0.33 (0.17–0.64) 0.54 (0.38–0.76)
2 0.55 (0.39–0.77) 0.71 (0.59–0.85)
3 0.74 (0.54–1.002) 0.87 (0.75–1.01)
4 1.28 (0.71–2.31) 1.02 (0.75–1.40)
Prior to Index Admission
One or More SNF Stays
Any Therapy
Chemotherapy 0.67 (0.52–0.87)
Radiation 1.68 (1.28–2.20) 1.18 (1.04–1.34)
Targeted Chemotherapy 2.34 (1.18–4.62)
HTN 0.74 (0.55–0.99) 0.82 (0.72–0.94)
Diabetes
COPD 1.16 (1.02–1.32)
Heart
Stroke 0.47 (0.25–0.89)
Cognitive 0.44 (0.27–0.69) 1.84 (1.17–2.88)
Alcohol 2.39 (1.23–4.63)
Depression 1.60 (1.08–2.38)
Index Hospital
Region (vs. West)
Northeast 1.98 (1.40–2.81)
Midwest 3.90 (2.21–6.88)
South 1.86 (1.20–2.88)
Location: Urban (vs. Rural) 2.01 (1.22–3.33) 0.69 (0.53–0.91)
Type: Teaching (vs. Non-teaching) 0.76 (0.60–0.96) 0.85 (0.76–0.96)
LOS 0.96 (0.94–0.99) 0.92 (0.86–0.99) 1.03 (1.01–1.05)
Discharge Year
*

Hazard Ratio

**

Grade I: well differentiated; differentiated, NOS

Grade 2: moderately differentiated; moderately differentiated; intermediate differentiation

Grade 3: poorly differentiated; differentiated

Grade 4: undifferentiated; anaplastic

Grade 9: cell type not determined, not stated or not applicable